Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison-Reference-Cited by-同舟云学术

Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison

Published:2019-03-07 Issue:5 Volume:19 Page:609-617
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Vargas C.¹²^ORCID,Balmaceda C.¹,Rodríguez F.³,Rojas R.¹,Giglio A.⁴,Espinoza M. A.¹⁵

Affiliation:

1. Unidad de Evaluación de Tecnologías en Salud, Centro de Investigación Clínica, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

2. Centre of Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Sydney, Australia

3. Faculty of Medicine, Universidad San Sebastián, Santiago, Chile

4. Programa de Medicina Interna, Complejo Asistencial Sótero del Río, Santiago, Chile

5. Departamento de Salud Pública, Pontificia Universidad Católica de Chile, Santiago, Chile

Funder

This study was conducted under strict clauses of independence. The sponsors did not contribute at all in the development of this research

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1580572

Reference42 articles.

1. EAU Guidelines on Renal Cell Carcinoma: 2014 Update

2. Renal cell carcinoma

3. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)

4. Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09